Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
3Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Cellectar Biosciences, Inc. (CLRB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
3Distinct source URLs
9High confidence
0.803Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Cellectar Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CAMPUS-100-LLC
CAMPUS-100-LLC
90%
Under the Second Amended HQ Lease, which was accounted for as a modification of the initial lease and went into effect upon the landlord’s delivery of the expanded space in March 2026, the Company wi…
IONETIX-CORPORATION
IONETIX-CORPORATION
90%
In December 2025, the Company announced a multi-year supply agreement with Ionetix Corporation for two critical alpha-emitting radioisotopes: Actinium-225 (Ac-225) and Astatine-211 (At-21).
NORTHSTAR-MEDICAL-RADIOISOTOPES
NORTHSTAR-MEDICAL-RADIOISOTOPES
90%
As it relates to CLR 121225, it was announced in late 2024 that the one of the sources for actinium would be Northstar Medical Radioisotopes.
ATOMVIE
ATOMVIE
80%
The finished PRCs are currently supplied by either AtomVie or SpectronRx.
SPECTRONRX
SPECTRONRX
80%
The finished PRCs are currently supplied by either AtomVie or SpectronRx.
Reciprocal relationship from KZIA graph: pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical tria…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CLRB graph: we experience unanticipated problems with our products, we may be subject to penalties, we may be unable to generate…
we experience unanticipated problems with our products, we may be subject to penalties, we may be unable to generate revenue from the sale of such products, our potential for generating positive cash…
Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in o…
o conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; ● restrictions on product manufacturing processes; ● restrictions on the marketing of a product; ● re…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CLRB graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CLRB graph: o conduct clinical trials, includ…
GLOBAL-DATA-RESEARCH-GROUP
GLOBAL-DATA-RESEARCH-GROUP
62%
f pediatric solid tumors. The American Cancer Society estimates that there will be 2,301 cases diagnosed in 2026. The median age at diagnosis is 16, and the median age of death is 18. We are focused …
Cellectar Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CLRB-DEBT-8697
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
CLRB-DEBT-8696
Warrants outstanding: 3032892
90%
xbrl warrant detail from xbrl 2026-03-31.
CLRB-DEBT
Debt stack $330,222
90%
Market cache reports total debt of $330,222.
Cellectar Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cellectar Biosciences, Inc..
Cellectar Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
CLRB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 19 tracked holders.
Cellectar Biosciences, Inc. Extended Supply Chain Network
